Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

collagenase clostridium histolyticum EN3835

An injectable formulation composed of the enzyme collagenase produced by the bacterium Clostridium histolyticum and containing a fixed ratio of purified class I (AUX-I) and class II (AUX-II) collagenases, with enzymatic debriding activity. Upon injection of collagenase clostridium histolyticum (CCH) EN3835 to the affected area(s), the collagenase hydrolyzes collagen in the collagen triple helix structure resulting in lysis and solubilization of collagen deposits and plaques. This may promote healing and reduce symptoms caused by excessive collagen deposits and accumulation, such as stiffness of the tissue and pain.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:C. clostridium histolyticum EN3835
CCH EN3835
US brand name:Xiaflex
Code name:EN 3835
EN-3835
EN3835
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search